Silvio Zaina1. 1. Department of Medical Sciences, Division of Health Sciences, Campus León, University of Guanajuato, León, Mexico.
Abstract
PURPOSE OF REVIEW: Epigenetic mechanisms of transcriptional regulation in atherosclerosis have gained an increasing interest in recent years. We focus on the relevance of DNA methylation, a well characterized epigenetic modification of the genome, as a biomarker and underlying mechanism of atherosclerosis. RECENT FINDINGS: A growing number of loci have been identified, which are good candidate biomarkers for atherosclerosis and provide novel insights into the molecular changes taking place in the diseased vessel. Understanding the global change in DNA methylation during atherosclerosis remains a challenge. Novel unfolding research avenues include the interplay between genetic variants and DNA methylation patterns, and the role of long noncoding RNAs as epigenetic regulators. SUMMARY: Epigenetics continues to represent a promising area of research in atherosclerosis. The full exploitation of cutting edge epigenomics will be decisive to define whether epigenetics will contribute to lower the burden of cardiovascular diseases.
PURPOSE OF REVIEW: Epigenetic mechanisms of transcriptional regulation in atherosclerosis have gained an increasing interest in recent years. We focus on the relevance of DNA methylation, a well characterized epigenetic modification of the genome, as a biomarker and underlying mechanism of atherosclerosis. RECENT FINDINGS: A growing number of loci have been identified, which are good candidate biomarkers for atherosclerosis and provide novel insights into the molecular changes taking place in the diseased vessel. Understanding the global change in DNA methylation during atherosclerosis remains a challenge. Novel unfolding research avenues include the interplay between genetic variants and DNA methylation patterns, and the role of long noncoding RNAs as epigenetic regulators. SUMMARY: Epigenetics continues to represent a promising area of research in atherosclerosis. The full exploitation of cutting edge epigenomics will be decisive to define whether epigenetics will contribute to lower the burden of cardiovascular diseases.
Authors: María del Pilar Valencia-Morales; Silvio Zaina; Holger Heyn; F Javier Carmona; Nuray Varol; Sergi Sayols; Enric Condom; José Ramírez-Ruz; Antonio Gomez; Sebastian Moran; Gertrud Lund; Dalia Rodríguez-Ríos; Gladys López-González; Magda Ramírez-Nava; Carmen de la Rocha; Alejandro Sanchez-Flores; Manel Esteller Journal: BMC Med Genomics Date: 2015-02-27 Impact factor: 3.063
Authors: Maria S Nazarenko; Anton V Markov; Igor N Lebedev; Maxim B Freidin; Aleksei A Sleptcov; Iuliya A Koroleva; Aleksei V Frolov; Vadim A Popov; Olga L Barbarash; Valery P Puzyrev Journal: PLoS One Date: 2015-04-09 Impact factor: 3.240
Authors: Geoffrey Istas; Ken Declerck; Maria Pudenz; Katarzyna Szarc Vel Szic; Veronica Lendinez-Tortajada; Montserrat Leon-Latre; Karen Heyninck; Guy Haegeman; Jose A Casasnovas; Maria Tellez-Plaza; Clarissa Gerhauser; Christian Heiss; Ana Rodriguez-Mateos; Wim Vanden Berghe Journal: Sci Rep Date: 2017-07-11 Impact factor: 4.379